{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-051588","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2022-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.162808+00:00","generated_at":"2026-06-26T03:37:54.066106+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Merck Q1 sales $15.9B (+50% YoY); Non-GAAP EPS $2.14; raises full-year guidance","bullets":["Sales $15.9B, +50% YoY (52% ex-FX); KEYTRUDA $4.8B (+23%), LAGEVRIO contributed $3.2B.","GAAP EPS $1.70 vs $1.08; Non-GAAP EPS $2.14 vs $1.16, both well above prior year.","Raises 2022 sales guidance to $56.9-$58.1B (17-19% growth); Non-GAAP EPS guidance $7.24-$7.36.","JANUVIA/JANUMET sales fell 5% to $1.2B; expect loss of EU/China exclusivity in Q3 2022.","Pipeline progress: FDA approvals for KEYTRUDA in MSI-H endometrial cancer and Lynparza in adjuvant breast cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-051588","json":"https://secwatch.observer/filing/0001104659-22-051588.json","markdown":"https://secwatch.observer/filing/0001104659-22-051588.md","text":"https://secwatch.observer/filing/0001104659-22-051588.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465922051588/0001104659-22-051588-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465922051588/tm2213615d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T03:37:54.066106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}